View in EDS

Hyperdiploidy impairs fetal hematopoietic progenitor fitness and differentiation enabling persistence of rare preleukemic aneuploid clones.

Saved in:
Bibliographic Details
Title: Hyperdiploidy impairs fetal hematopoietic progenitor fitness and differentiation enabling persistence of rare preleukemic aneuploid clones.
Authors: Thampi N; Josep Carreras Leukemia Research Institute, Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain; Red Española de Terápias Avanzadas (TERAV). Instituto de Salud Carlos III, Barcelona, Spain; Spanish National Cancer Network (CIBERONC). Instituto de Salud Carlos III, Barcelona, Spain., Calvo C; Josep Carreras Leukemia Research Institute, Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain; Red Española de Terápias Avanzadas (TERAV). Instituto de Salud Carlos III, Barcelona, Spain; Spanish National Cancer Network (CIBERONC). Instituto de Salud Carlos III, Barcelona, Spain., Rodríguez-Cortez V; Josep Carreras Leukemia Research Institute, Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain; Red Española de Terápias Avanzadas (TERAV). Instituto de Salud Carlos III, Barcelona, Spain; Spanish National Cancer Network (CIBERONC). Instituto de Salud Carlos III, Barcelona, Spain., Martínez-Moreno A; Josep Carreras Leukemia Research Institute, Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain; Red Española de Terápias Avanzadas (TERAV). Instituto de Salud Carlos III, Barcelona, Spain; Spanish National Cancer Network (CIBERONC). Instituto de Salud Carlos III, Barcelona, Spain., Roca-Ho H; Josep Carreras Leukemia Research Institute, Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain; Red Española de Terápias Avanzadas (TERAV). Instituto de Salud Carlos III, Barcelona, Spain; Spanish National Cancer Network (CIBERONC). Instituto de Salud Carlos III, Barcelona, Spain., Vinyoles M; Josep Carreras Leukemia Research Institute, Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain; Red Española de Terápias Avanzadas (TERAV). Instituto de Salud Carlos III, Barcelona, Spain; Spanish National Cancer Network (CIBERONC). Instituto de Salud Carlos III, Barcelona, Spain., Bueno C; Josep Carreras Leukemia Research Institute, Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain; Red Española de Terápias Avanzadas (TERAV). Instituto de Salud Carlos III, Barcelona, Spain; Spanish National Cancer Network (CIBERONC). Instituto de Salud Carlos III, Barcelona, Spain., Espinosa-Aroca L; Josep Carreras Leukemia Research Institute, Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain; Red Española de Terápias Avanzadas (TERAV). Instituto de Salud Carlos III, Barcelona, Spain; Spanish National Cancer Network (CIBERONC). Instituto de Salud Carlos III, Barcelona, Spain., Pablo-Fontecha V; August Pi i Sunyer Biomedical Research Institute (IDIBAPS) and CIBEREHD, Barcelona, Spain., Camps J; August Pi i Sunyer Biomedical Research Institute (IDIBAPS) and CIBEREHD, Barcelona, Spain; Cell Biology and Medical Genetics Unit, Department of Cell Biology, Physiology and Immunology, School of Medicine, Autonomous University of Barcelona, Barcelona, Spain., de la Fuente-González A; Departament of Biochemistry and Molecular Biology, Instituto Universitario de Oncología (IUOPA), University of Oviedo, Oviedo, Spain., Puente XS; Spanish National Cancer Network (CIBERONC). Instituto de Salud Carlos III, Barcelona, Spain; Departament of Biochemistry and Molecular Biology, Instituto Universitario de Oncología (IUOPA), University of Oviedo, Oviedo, Spain., Solé F; Josep Carreras Leukemia Research Institute, Catalan Institute of Oncology (ICO), Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain., Foijer F; European Research Institute for the Biology of Ageing (ERIBA), University of Groningen, University Medical Center Groningen, Groningen, the Netherlands., Menéndez P; Josep Carreras Leukemia Research Institute, Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain; Red Española de Terápias Avanzadas (TERAV). Instituto de Salud Carlos III, Barcelona, Spain; Spanish National Cancer Network (CIBERONC). Instituto de Salud Carlos III, Barcelona, Spain; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain; Department of Biomedicine, School of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain; Pediatric Cancer Centre Barcelona-Institut de Recerca Sant Joan de Deu (PCCB-SJD), Barcelona, Spain. Electronic address: pmenendez@carrerasresearch.org., Molina O; Josep Carreras Leukemia Research Institute, Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain; Red Española de Terápias Avanzadas (TERAV). Instituto de Salud Carlos III, Barcelona, Spain; Spanish National Cancer Network (CIBERONC). Instituto de Salud Carlos III, Barcelona, Spain; Genetics Section, Department of Physiological Sciences, School of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain. Electronic address: omolina@ub.edu.
Source: Cell reports [Cell Rep] 2026 Mar 27; Vol. 45 (4), pp. 117173. Date of Electronic Publication: 2026 Mar 27.
Publication Type: Journal Article
Journal Info: Publisher: Cell Press Country of Publication: United States NLM ID: 101573691 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2211-1247 (Electronic) NLM ISO Abbreviation: Cell Rep Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41903134
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Hyperdiploidy impairs fetal hematopoietic progenitor fitness and differentiation enabling persistence of rare preleukemic aneuploid clones.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Thampi+N%22">Thampi N</searchLink>; Josep Carreras Leukemia Research Institute, Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain; Red Española de Terápias Avanzadas (TERAV). Instituto de Salud Carlos III, Barcelona, Spain; Spanish National Cancer Network (CIBERONC). Instituto de Salud Carlos III, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Calvo+C%22">Calvo C</searchLink>; Josep Carreras Leukemia Research Institute, Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain; Red Española de Terápias Avanzadas (TERAV). Instituto de Salud Carlos III, Barcelona, Spain; Spanish National Cancer Network (CIBERONC). Instituto de Salud Carlos III, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Rodríguez-Cortez+V%22">Rodríguez-Cortez V</searchLink>; Josep Carreras Leukemia Research Institute, Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain; Red Española de Terápias Avanzadas (TERAV). Instituto de Salud Carlos III, Barcelona, Spain; Spanish National Cancer Network (CIBERONC). Instituto de Salud Carlos III, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Martínez-Moreno+A%22">Martínez-Moreno A</searchLink>; Josep Carreras Leukemia Research Institute, Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain; Red Española de Terápias Avanzadas (TERAV). Instituto de Salud Carlos III, Barcelona, Spain; Spanish National Cancer Network (CIBERONC). Instituto de Salud Carlos III, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Roca-Ho+H%22">Roca-Ho H</searchLink>; Josep Carreras Leukemia Research Institute, Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain; Red Española de Terápias Avanzadas (TERAV). Instituto de Salud Carlos III, Barcelona, Spain; Spanish National Cancer Network (CIBERONC). Instituto de Salud Carlos III, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Vinyoles+M%22">Vinyoles M</searchLink>; Josep Carreras Leukemia Research Institute, Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain; Red Española de Terápias Avanzadas (TERAV). Instituto de Salud Carlos III, Barcelona, Spain; Spanish National Cancer Network (CIBERONC). Instituto de Salud Carlos III, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Bueno+C%22">Bueno C</searchLink>; Josep Carreras Leukemia Research Institute, Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain; Red Española de Terápias Avanzadas (TERAV). Instituto de Salud Carlos III, Barcelona, Spain; Spanish National Cancer Network (CIBERONC). Instituto de Salud Carlos III, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Espinosa-Aroca+L%22">Espinosa-Aroca L</searchLink>; Josep Carreras Leukemia Research Institute, Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain; Red Española de Terápias Avanzadas (TERAV). Instituto de Salud Carlos III, Barcelona, Spain; Spanish National Cancer Network (CIBERONC). Instituto de Salud Carlos III, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Pablo-Fontecha+V%22">Pablo-Fontecha V</searchLink>; August Pi i Sunyer Biomedical Research Institute (IDIBAPS) and CIBEREHD, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Camps+J%22">Camps J</searchLink>; August Pi i Sunyer Biomedical Research Institute (IDIBAPS) and CIBEREHD, Barcelona, Spain; Cell Biology and Medical Genetics Unit, Department of Cell Biology, Physiology and Immunology, School of Medicine, Autonomous University of Barcelona, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22de+la+Fuente-González+A%22">de la Fuente-González A</searchLink>; Departament of Biochemistry and Molecular Biology, Instituto Universitario de Oncología (IUOPA), University of Oviedo, Oviedo, Spain.<br /><searchLink fieldCode="AU" term="%22Puente+XS%22">Puente XS</searchLink>; Spanish National Cancer Network (CIBERONC). Instituto de Salud Carlos III, Barcelona, Spain; Departament of Biochemistry and Molecular Biology, Instituto Universitario de Oncología (IUOPA), University of Oviedo, Oviedo, Spain.<br /><searchLink fieldCode="AU" term="%22Solé+F%22">Solé F</searchLink>; Josep Carreras Leukemia Research Institute, Catalan Institute of Oncology (ICO), Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Foijer+F%22">Foijer F</searchLink>; European Research Institute for the Biology of Ageing (ERIBA), University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Menéndez+P%22">Menéndez P</searchLink>; Josep Carreras Leukemia Research Institute, Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain; Red Española de Terápias Avanzadas (TERAV). Instituto de Salud Carlos III, Barcelona, Spain; Spanish National Cancer Network (CIBERONC). Instituto de Salud Carlos III, Barcelona, Spain; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain; Department of Biomedicine, School of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain; Pediatric Cancer Centre Barcelona-Institut de Recerca Sant Joan de Deu (PCCB-SJD), Barcelona, Spain. Electronic address: pmenendez@carrerasresearch.org.<br /><searchLink fieldCode="AU" term="%22Molina+O%22">Molina O</searchLink>; Josep Carreras Leukemia Research Institute, Department of Biomedicine, School of Medicine, University of Barcelona, Barcelona, Spain; Red Española de Terápias Avanzadas (TERAV). Instituto de Salud Carlos III, Barcelona, Spain; Spanish National Cancer Network (CIBERONC). Instituto de Salud Carlos III, Barcelona, Spain; Genetics Section, Department of Physiological Sciences, School of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain. Electronic address: omolina@ub.edu.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101573691%22">Cell reports</searchLink> [Cell Rep] 2026 Mar 27; Vol. 45 (4), pp. 117173. <i>Date of Electronic Publication: </i>2026 Mar 27.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Cell+Press%22">Cell Press </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101573691 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2211-1247 (Electronic) <i>NLM ISO Abbreviation: </i>Cell Rep <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41903134
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.celrep.2026.117173
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 117173
    Titles:
      – TitleFull: Hyperdiploidy impairs fetal hematopoietic progenitor fitness and differentiation enabling persistence of rare preleukemic aneuploid clones.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Thampi N
      – PersonEntity:
          Name:
            NameFull: Calvo C
      – PersonEntity:
          Name:
            NameFull: Rodríguez-Cortez V
      – PersonEntity:
          Name:
            NameFull: Martínez-Moreno A
      – PersonEntity:
          Name:
            NameFull: Roca-Ho H
      – PersonEntity:
          Name:
            NameFull: Vinyoles M
      – PersonEntity:
          Name:
            NameFull: Bueno C
      – PersonEntity:
          Name:
            NameFull: Espinosa-Aroca L
      – PersonEntity:
          Name:
            NameFull: Pablo-Fontecha V
      – PersonEntity:
          Name:
            NameFull: Camps J
      – PersonEntity:
          Name:
            NameFull: de la Fuente-González A
      – PersonEntity:
          Name:
            NameFull: Puente XS
      – PersonEntity:
          Name:
            NameFull: Solé F
      – PersonEntity:
          Name:
            NameFull: Foijer F
      – PersonEntity:
          Name:
            NameFull: Menéndez P
      – PersonEntity:
          Name:
            NameFull: Molina O
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 27
              M: 03
              Text: 2026 Mar 27
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 2211-1247
          Numbering:
            – Type: volume
              Value: 45
            – Type: issue
              Value: 4
          Titles:
            – TitleFull: Cell reports
              Type: main
ResultId 1